The trivial size of these insider sales provides no actionable signal. Focus on the company's strong fundamental momentum and the integration of Soleno's VYKAT XR. Monitor next quarter for any material change in insider trading patterns.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $153.90entry
- T+1 · 6mo ago +0.19%α −0.85% · $154.19
- T+5 · 6mo ago +0.91%α −1.39% · $155.30
- T+20 · 5mo ago +1.64%α −0.62% · $156.42
- T+60 · 3mo ago −2.00%α −8.02% · $150.82
Price Chart
How similar events traded
Executive Summary
Two NBIX directors sold $2.96M in shares over a 4-day window, representing a trivial 0.019% of market cap. Sales occurred after a strong Q1 earnings beat (+42% revenue YoY) and just before the close of the $2.9B Soleno acquisition, suggesting routine portfolio diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- Director Richard F. Pops sold 15,000 shares at $157.65 for $2.36M on May 15, 2026
- Director Leslie V. Norwalk sold 3,810 shares at $155.01 for $0.59M on May 12, 2026
- Total cluster value of $2.96M is only 0.019% of NBIX's $15.9B market cap
- Sales follow Q1 2026 net product sales of $811M (+44% YoY) and the announced $2.9B Soleno acquisition
Financial Impact
Insider sales of $2.96M are immaterial relative to $15.9B market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1779141071610 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers